Company: PRGO
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001585364-25-000122
Chunk: 127

Company: PERRIGO Co plc
Filing Date: 2025-08-06
Form: 10-Q
Item: Part II, Item 1
Chunk 127
---
 the first quarter in the prior year, and lower net sales in the Oral Care category of $16.0 million. These were partially offset by higher net sales in the Nutrition category of $23.9 million, stemming from recovery in the infant formula business, as well as higher net sales in the Upper Respiratory category of $12.1 million due to higher incidence levels of cough cold compared to the prior year.

CSCA net sales by product category were as follows:

SalesSix Months Ended(in millions, except percentages)June 28, 2025June 29, 2024$ Change% ChangeUpper Respiratory$261.2 $249.1 $12.1 4.9 %Digestive Health212.7 248.2 (35.5)(14.3)%Nutrition200.3 176.7 23.6 13.4 %Pain and Sleep-Aids156.8 164.2 (7.4)(4.5)%Healthy Lifestyle144.1 140.4 3.7 2.6 %Oral Care122.0 137.9 (15.9)(11.5)%Skin Care106.3 106.7 (0.4)(0.4)%Women's Health33.7 44.0 (10.3)(23.4)%VMS3.8 9.5 (5.7)(60.0)%Other CSCA1.8 1.6 0.2 12.5 %Total CSCA$1,242.8 $1,278.3 $(35.5)(2.8)%

Sales drivers in each category are provided below: 

•Upper Respiratory: Net sales of $261.2 million increased 4.9% due primarily to higher incidence levels of cough cold compared to the prior year first quarter, higher net sales of allergy products, including Nasonex®, Fluticasone and Fexofenadine, and new business wins. This growth was partially offset by previously disclosed net lost distribution of lower margin products;

•Digestive Health: Net sales of $212.7 million decreased 14.3% due primarily to previously disclosed net lost distribution of lower margin products in U.S. Store Brand and lower consumption of proton pump inhibitors, including Omeprazole, Esomeprazole and Lansoprazole, despite Perrigo share